论文部分内容阅读
目的探讨32P玻璃微球行经肝动脉栓塞内照射的安全性和有效性。方法原发性肝癌26例，经肝动脉选择性插管后，用32P玻璃微球与超液化碘油混合后作栓塞。治疗放射剂量为75～150Gy。结果术后均有肝功能一过性异常，2周后逐渐恢复至术前水平，血象及肾功能无异常改变。术后无严重并发症。微球主要分布于肝内，癌／肝放射比为3.5:1。随访3～19个月23例（88.4％）。病灶有缩小，体积缩小50％以上11例（42．3％）。9例（75．0％）生存期＞1年，中位生存时间为8．1月。结论32P玻璃微球作为一种新型栓塞内放射材料，具有半衰期适中，射程适宜的优势。初步临床应用表明为行肝动脉栓塞内照射安全、有效。
Objective To investigate the safety and efficacy of intraluminal arterial embolization in 32P glass microspheres. Methods Primary liver cancer was performed in 26 patients. After selective hepatic artery catheterization, 32P glass microspheres were mixed with hyperlipidic lipiodol for embolization. The therapeutic radiation dose is 75 to 150 Gy. Results There was a transient abnormality of liver function after operation. After 2 weeks, it gradually returned to the preoperative level. There was no abnormal change in blood and renal function. No serious complications after surgery. The microspheres are mainly distributed in the liver with a cancer/liver radioactivity ratio of 3.5:1. Follow-up 3 to 19 months in 23 cases (88.4%). The lesions were reduced and the volume was reduced by more than 50% in 11 cases (42.3%). Nine patients (75.0%) had a survival period of >1 year and a median survival time of 8.1 months. Conclusion The 32P glass microspheres as a new type of intraluminal embolization materials have the advantages of moderate half-life and appropriate range. The preliminary clinical application showed that it is safe and effective for internal hepatic artery embolization.